SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-135281
Filing Date
2024-05-09
Accepted
2024-05-09 16:15:41
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d791133d8k.htm   iXBRL 8-K 24883
2 EX-99.1 d791133dex991.htm EX-99.1 31845
6 GRAPHIC g791133g0504021731180.jpg GRAPHIC 3298
  Complete submission text file 0001193125-24-135281.txt   190571

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20240509.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20240509_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20240509_pre.xml EX-101.PRE 11264
18 EXTRACTED XBRL INSTANCE DOCUMENT d791133d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 24930876
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)